for the treatment of obstructive lung diseases. It acts by blocking atrovent and asthma receptors in the lung, inhibiting bronchoconstriction and mucus secretion. atrovent and asthma is a quaternary amine and therefore does not diffuse into the blood, which prevents systemic side effects. Ipratropium is also combined with albuterol (salbutamol).

389.457 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability ?Protein binding 0 to 9% in vitroMetabolism HepaticHalf life 2 hoursExcretion ?Therapeutic considerationsPregnancy cat. B(US)Legal status POM(UK)Routes InhalationIpratropium atrovent and asthma ipratropium bromide, trade name Atrovent) atrovent and asthma an anticholinergic drug administered by inhalation atrovent and asthma the treatment of obstructive lung diseases. It acts by blocking muscarinic atrovent and asthma in the lung, inhibiting bronchoconstriction and mucus secretion. It is a quaternary atrovent and asthma and therefore does not diffuse into the blood, which prevents systemic side effects. Ipratropium is also combined with albuterol (salbutamol) (trade names Combivent and Duoneb) for the atrovent and asthma of obstructive lung diseases. It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion. It is a derivative of atropine[1] but is a derivative of atropine[1] but is a non-selective muscarinic atrovent and asthma and does not atrovent and asthma into the blood, which prevents systemic.

(trade names Combivent and Duoneb) for the management of asthma.Side effects are as those for other.